Elan to appeal EU Tysabri rejection in Crohn's
Reuters - USA
LONDON, July 20 (Reuters) - Ireland's Elan Corp (ELN.I: Quote, Profile, Research) and US partner Biogen Idec (BIIB.O: Quote, Profile, Research) said on ...
See all stories on this topic

Questions and Answers on Recommendation for the Refusal of the ...
PharmaLive.com (press release) - Newtown,PA,USA
What is happening for TYSABRI for the treatment of multiple sclerosis? There are no consequences of this opinion on the use of TYASBRI, which also contains ...
See all stories on this topic

Friday's Health Winners & Losers
TheStreet.com - USA
In the US, Tysabri for moderate to severe Crohn's goes before a panel of medical advisers to the Food and Drug Administration on July 31. ...
See all stories on this topic